Current report no. 29 / 2019

Date: **2019-11-10**

Abbreviated name of the issuer MABION S.A.

Subject: Responses to round two of inquiries in scope of the registration procedure of MabionCD20 in the European Medicines Agency

Legal grounds: art. 17 section 1 of the Market Abuse Regulation – inside information.

Content of report:

In reference to current report no. 20/2019 dated 1 July 2019 and previous communication concerning the application for marketing authorisation of the drug under the working name of MabionCD20 by the European Medicines Agency (EMA) filed by Mabion S.A. ("Company"), the Company's Management Board hereby informs that on 10 November 2019 it obtained from the company contracted to deposit responses to round two of enquiries (day 180) in the scope of the registration procedure of MabionCD20 a confirmation of its effective entry into the EMA electronic system.

The response allows the Agency to continue evaluation of the application. At present, the Company will await the opinion of the Committee for Medicinal Products for Human Use (CHMP).

The Company hereby informs that submission of the responses in question does not guarantee approval of the product by the European Medicines Agency.